Prosecution Insights
Last updated: April 18, 2026
Application No. 18/430,788

MULTI-EFFECTOR CRISPR BASED DIAGNOSTIC SYSTEMS

Non-Final OA §112§DP
Filed
Feb 02, 2024
Examiner
PAGE, BRENT T
Art Unit
1663
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
President and Fellows of Harvard College
OA Round
3 (Non-Final)
83%
Grant Probability
Favorable
3-4
OA Rounds
2y 6m
To Grant
93%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allow Rate
1217 granted / 1474 resolved
+22.6% vs TC avg
Moderate +11% lift
Without
With
+10.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
33 currently pending
Career history
1507
Total Applications
across all art units

Statute-Specific Performance

§101
5.8%
-34.2% vs TC avg
§103
18.4%
-21.6% vs TC avg
§102
16.8%
-23.2% vs TC avg
§112
44.7%
+4.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1474 resolved cases

Office Action

§112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 02/27/2026 has been entered. Claims 111-117, 119-125 and 127-131 are pending. Claims 115-117, 119-124 and 127-130 remain withdrawn as being drawn to nonelected claims. Claims 111-114, 125 and 131 are examined herein on the merits. Priority The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of 35 U.S.C. 112(a) or the first paragraph of pre-AIA 35 U.S.C. 112, except for the best mode requirement. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, Application No.62556408, fails to provide adequate support or enablement in the manner provided by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph for one or more claims of this application. Accordingly, the priority date for the claims as currently written is 12/22/2017 with support provided by provisional 62610121. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 112 and 113 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. Claims 112 and 113 recite “wherein the Type VI accessory protein(s)”. There is insufficient antecedent basis for this limitation in the claim. Double Patenting Applicant’s amendments, filed on 02/27/2026 when taken together with the claim amendments have overcome the rejection of the claims under obvious type double patenting. Claims 111, 114, 125 and 131 are allowed. The earliest mentions of Csx27 and Csx28 are all within a year of the filing date and appear to be by the instant Inventors. The concept of combining Csx27 or Csx28 with a type III polypeptide appears to be free of the prior art. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRENT T PAGE whose telephone number is (571)272-5914. The examiner can normally be reached M-F 7-4 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amjad Abraham can be reached at 5712707058. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRENT T PAGE/Primary Examiner, Art Unit 1663
Read full office action

Prosecution Timeline

Feb 02, 2024
Application Filed
Apr 05, 2025
Non-Final Rejection — §112, §DP
Aug 08, 2025
Response Filed
Dec 02, 2025
Final Rejection — §112, §DP
Feb 04, 2026
Response after Non-Final Action
Feb 27, 2026
Request for Continued Examination
Mar 09, 2026
Response after Non-Final Action
Apr 04, 2026
Non-Final Rejection — §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600980
NOVEL DISEASE RESISTANT MELON PLANTS
2y 5m to grant Granted Apr 14, 2026
Patent 12600975
COMPOSITIONS AND METHODS FOR MODIFYING GENOMES
2y 5m to grant Granted Apr 14, 2026
Patent 12599098
SOYBEAN CULTIVAR 22140806
2y 5m to grant Granted Apr 14, 2026
Patent 12593765
SIMULTANEOUS GENE EDITING AND HAPLOID INDUCTION
2y 5m to grant Granted Apr 07, 2026
Patent 12593787
PLANTS AND SEEDS OF CORN VARIETY CV989440
2y 5m to grant Granted Apr 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
83%
Grant Probability
93%
With Interview (+10.6%)
2y 6m
Median Time to Grant
High
PTA Risk
Based on 1474 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month